Homepage / Technology / Cramer: Mea culpa! This stock's action is why I say small-cap biotechs are only for speculation
Les Gambling establishments en Ligne en France 2024 200% Reward + 300 Free Rotates LevelUp Internet casino Melbourne En İyi ve Güvenilir Casino Siteleri Canlı Casino Siteleri 2023 Listesi En İyi ve Güvenilir Casino Siteleri Canlı Casino Siteleri 2023 Listesi Le meilleur casino en ligne franзais Extra Casino avec le dйpфt minimal le in addition bas Yeni Casino Siteleri ᐈ Çevrimiçi Kumarhaneler Mart 2024 Les gambling establishments en ligne proposent une grande variйtй de jeux de internet casino gratuits. Türkiye’deki Resmi Web Sitesi Google Play, Türkiye’de kumar oyunlarına izin verecek Her Gün Tatil Olsa ORDU’DA PAZARTESİ GÜNÜ FINDIK FİYATI NASIL? كازينو اون لاين الكازينوهات الممتازة على الإنترنت ألعاب الكازينو المباشرة مينا كازينو العر Google Play, Türkiye’de kumar oyunlarına izin verecek Domain Sorgulama & Domain Fýrsatlarý Canlı Casino Siteleri: 2024 Güvenilir Siteler Seçilmiştir Golden Easter Slot İncelemesi 2024, Demoyu Ücretsiz Oynayın Golden Easter Slot İncelemesi 2024, Demoyu Ücretsiz Oynayın 1xbet Türkiye Giriş Empieza Kayıt 202 Kumar Ve Kumarhaneler Hakkında Pek İlginç 21 Bilgi Kumarhane Doğru Yazımı Nedir? Tdk Ile Kumarhane Kelimesinin Doğru Yazılışı! Mobilbahiste En İyi Kumar Bonusları Ve Kazançlar Mobilbahis Giriş Sayfası On Line Casino Siteleri En Iyi Casino Siteleri 2024 Mostbet: Türkiye’de Internet Casino Mostbet Online Slotlar Ve Canlı-casin Pin Up Casino Oyna Türkiye, Pinup’un Sah Web Sites Ifade Haberleri Son Dakika Ifade Hakkında Güncel Haber Ve Bilgiler “önceliğimiz Transferin Önünü Açmak, Görüştüğümüz Yerler Var” On Line Casino Nuh’un Gemisi Deluxe Resort & Spa, Kıbrıs Bonus Veren Siteler 3 000 Den Fazla Online Oyunu Ücretsiz Oyna En Tehlikeli Kumar Oyunu Ekşi Sözlük Deneme Bonusu Veren Siteler Deneme Bonusu 2024 Explore the Magic of WildCardCity Güvenilir Bahis Siteleri En İyi Kumar Siteleri Balıkesir Triatlonuna Avrupadan Ödül Tricks of the Aviator gambling establishment game by Spribe Çevrim Içi Kumar Siteleri “bonus” Yalanıyla Kandırıyor En Güvenilir Canlı On Line Casino Siteleri Xbetting-tips Com Uncovering the Abundant Tapestry of Ozwin Gambling establishment Evaluating Board Portal Providers Uncovering the Wealthy Tapestry of Ozwin On line casino Electronic Data Area Providers Evaluation Cobra Internet casino: Raising the Australian On the internet Video gaming Practical experience 4 Things to Search for in Safeguarded Cloud Safe-keeping Fastpay On line casino Australia – Simple and No-Taxation Wagering Web page officielle franзaise de Joka Gambling establishment The Software Development Universe Game Woo Internet casino – Enjoy Slot machine games around australia Ostdeutsche Biersorten What Are Virtual Data Rooms? Vitamin D Receptor Polymorphisms Revue du Casino BlackLabel Faktory, kterй ovlivnujн hodnocenн ceskэch online kasin How to Make the Most of Your Web Development Organization and Advertising Efforts L’essor des casinos en ligne en France Boost Meeting Efficiency With Boardroom Technology Developments WildJoker Casino WildCardCity On line casino – Guaranteed Australian Gambling Portal WildCardCity Casino – The Ideal On the internet Gambling establishment within australia Modern Technologies Produce Sharing Documents Online Faster and More Protect Free Virtual Info Room pertaining to Speedy Due Diligence A Review of Data Area Software For people who do buiness Five Board Bedroom Features Which will help You Acquire a More Productive Boardroom Electronic Systems To your Business Understanding Legal Terms and Laws in Today’s World The Laws and Contracts of Hollywood: A Sunset Blvd. Tale Legal Discussion Between Johnny Cash and Antonin Scalia Legal Insights: What Teens Should Know Legal Issues and Exceptions: What You Need to Know Legal Insights and Expert Analysis Celebrity Dialogue: Legal Matters in the 21st Century Famous Personalities Discuss Legal Issues The Boys in the Boat: Legal Advisors and The Quest for Legal Knowledge Understanding Legal Matters: Q&A on Criminal Law, Joint Ventures, and More Enticing Title The Departed: Understanding Basic Work Requirements and Legal Rights Youth Slang Blog Article Legal Insights: A Journey into the World of Law The Ins and Outs of Legal Matters: Everything You Need to Know Legal Insights and Trends: A Rap Guide Mysterious Legal Matters Unveiled Insights and Information: Understanding Various Laws and Regulations Famous People of the 21st Century The Circle of Legal Life The Intersection of Fashion Law, Legal Translation, and THC Oil: A Modern Legal Guide Legal Q&A: Understanding Joinder Federal Rules and More Understanding Legal Terms and Conditions: A Comprehensive Guide Understanding Legal Documentation in a Fun Way! Understanding Legal Aspects: From Islamic Law of Inheritance to Farm Law Protests Understanding Legal Rights: A Guide to Legal Regulations and Requirements Understanding Legal Guidelines and Agreements Famous 21st Century People in Conversation Mysterious Legal Matters Unveiled Legal Matters and Real Estate: A Conversation Between Cameron Boyce and Donald Trump Understanding Legal Expertise and Why It Matters Legal FAQs and Expert Services Understanding Legal Ramifications: Common Law Ontario Health Benefits and More The Ins and Outs of Legal Requirements: From FBI Academy Physical Requirements to Silver Lake Fishing Rules The Legal Underworld: Understanding the Significance of Laws and Rights Legal Conversations: A Dialogue Between Jon Jones and Chadwick Boseman Legal Beats: Bobcats, Real Estate, Babysitting, and More

Technology

Cramer: Mea culpa! This stock's action is why I say small-cap biotechs are only for speculation

After the stock of Alder BioPharmaceuticals fell off a cliff, plummeting to just over $12 on Thursday from its $55 peak two years ago, Jim Cramer had to find out what went wrong.

The decline was only accelerated on Wednesday when the small-capitalization company announced a huge secondary offering and the stock lost almost 20 percent of its value.

The stock recovered slightly when the offering was priced at $10 a share, which made the “Mad Money” host wonder if the worst is finally behind the development-stage biotechnology name.

Alder’s primary business is focused on developing genetically engineered antibodies designed to treat various diseases. Along with its top drug, a Phase 3 migraine treatment, it has a migraine treatment in development and an arthritis drug in the early stages of clinical trials.

“The data here seemed pretty good, at least until a few weeks ago,” Cramer said. “Chronic migraines are a serious problem, one that costs businesses $13 billion every year as a result of lost workdays. So a drug that could effectively prevent migraines would be very, very valuable, not just to the people who suffer from this painful condition, but also for their employers.”

Plus, the only FDA-approved treatment for migraines is Allergan’s Botox, and based on Alder’s Phase 2 data, its migraine drug would likely be much more effective.

Cramer bought into Alder’s model and came out in support of its stock when the company’s CEO, Randy Schatzman, came on “Mad Money” in June of 2015 and again in January of 2016.

“I was very supportive of the stock when it was a heck of a lot higher, so I definitely need to eat some crow here about Alder. From that last interview through today, Alder’s lost 58 percent of its value. Mea culpa!” the “Mad Money” host said. “This is why I try so hard to recommend small-cap biotechs for speculation only, meaning you should only ever buy them with money that you can afford to lose.”

Alder’s first obstacle was its Phase 3 trial results for its leading migraine drug. While much of the data were favorable, they were also in-line with expectations, causing a selloff in the stock.

Out of the eight analysts covering Alder, only one from Credit Suisse was bearish, but that report, which downgraded the stock to a “neutral” rating and slashed its price target from $30 to $17, seemed responsible for the stock’s action.

The report cited a competitive market where rivals’ drugs work better, on average, based on clinical data, and those rivals have the capacity to release their treatments sooner than Alder.

Even after rallying on Thursday, Cramer said many bears agree that Alder’s shares deserve to trade higher then where they are currently trading.

“I think Alder BioPharmaceuticals sold off too hard in the wake of the data it released two weeks ago,” Cramer said. “Migraines are a huge category. I think there’s definitely a place for their drug. Even the bears think it could [do] $300 million in annual peak sales, and this is now just a $600 million company. Plus, at these levels, I think that Alder could be a terrific takeover target if the drug works better. I know this stock has burned people on the way down, but it’s got a viable drug and we care about where a stock’s going on this show, not where it’s been. In my view, Alder’s been de-risked down here, and I think it’s worth speculating on.”

Questions for Cramer?
Call Cramer: 1-800-743-CNBC

Want to take a deep dive into Cramer’s world? Hit him up!
Mad Money TwitterJim Cramer TwitterFacebookInstagramVine

Questions, comments, suggestions for the “Mad Money” website? madcap@cnbc.com

Source: Tech CNBC
Cramer: Mea culpa! This stock's action is why I say small-cap biotechs are only for speculation

Comments are closed.